Literature DB >> 18524832

Interaction of hepatitis C virus nonstructural protein 5A with core protein is critical for the production of infectious virus particles.

Takahiro Masaki1, Ryosuke Suzuki, Kyoko Murakami, Hideki Aizaki, Koji Ishii, Asako Murayama, Tomoko Date, Yoshiharu Matsuura, Tatsuo Miyamura, Takaji Wakita, Tetsuro Suzuki.   

Abstract

Nonstructural protein 5A (NS5A) of the hepatitis C virus (HCV) possesses multiple and diverse functions in RNA replication, interferon resistance, and viral pathogenesis. Recent studies suggest that NS5A is involved in the assembly and maturation of infectious viral particles; however, precisely how NS5A participates in virus production has not been fully elucidated. In the present study, we demonstrate that NS5A is a prerequisite for HCV particle production as a result of its interaction with the viral capsid protein (core protein). The efficiency of virus production correlated well with the levels of interaction between NS5A and the core protein. Alanine substitutions for the C-terminal serine cluster in domain III of NS5A (amino acids 2428, 2430, and 2433) impaired NS5A basal phosphorylation, leading to a marked decrease in NS5A-core interaction, disturbance of the subcellular localization of NS5A, and disruption of virion production. Replacing the same serine cluster with glutamic acid, which mimics the presence of phosphoserines, partially preserved the NS5A-core interaction and virion production, suggesting that phosphorylation of these serine residues is important for virion production. In addition, we found that the alanine substitutions in the serine cluster suppressed the association of the core protein with viral genome RNA, possibly resulting in the inhibition of nucleocapsid assembly. These results suggest that NS5A plays a key role in regulating the early phase of HCV particle formation by interacting with core protein and that its C-terminal serine cluster is a determinant of the NS5A-core interaction.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18524832      PMCID: PMC2519576          DOI: 10.1128/JVI.00826-08

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  58 in total

1.  National Institutes of Health Consensus Development Conference: management of hepatitis C: 2002.

Authors:  Leonard B Seeff; Jay H Hoofnagle
Journal:  Hepatology       Date:  2002-11       Impact factor: 17.425

2.  Electroporation in 'intracellular' buffer increases cell survival.

Authors:  M J van den Hoff; A F Moorman; W H Lamers
Journal:  Nucleic Acids Res       Date:  1992-06-11       Impact factor: 16.971

3.  Production of infectious hepatitis C virus in tissue culture from a cloned viral genome.

Authors:  Takaji Wakita; Thomas Pietschmann; Takanobu Kato; Tomoko Date; Michiko Miyamoto; Zijiang Zhao; Krishna Murthy; Anja Habermann; Hans-Georg Kräusslich; Masashi Mizokami; Ralf Bartenschlager; T Jake Liang
Journal:  Nat Med       Date:  2005-06-12       Impact factor: 53.440

4.  E6AP ubiquitin ligase mediates ubiquitylation and degradation of hepatitis C virus core protein.

Authors:  Masayuki Shirakura; Kyoko Murakami; Tohru Ichimura; Ryosuke Suzuki; Tetsu Shimoji; Kouichirou Fukuda; Katsutoshi Abe; Shigeko Sato; Masayoshi Fukasawa; Yoshio Yamakawa; Masahiro Nishijima; Kohji Moriishi; Yoshiharu Matsuura; Takaji Wakita; Tetsuro Suzuki; Peter M Howley; Tatsuo Miyamura; Ikuo Shoji
Journal:  J Virol       Date:  2006-11-15       Impact factor: 5.103

5.  The lipid droplet binding domain of hepatitis C virus core protein is a major determinant for efficient virus assembly.

Authors:  Anna Shavinskaya; Steeve Boulant; Francois Penin; John McLauchlan; Ralf Bartenschlager
Journal:  J Biol Chem       Date:  2007-10-17       Impact factor: 5.157

6.  The hepatitis C virus core protein interacts with NS5A and activates its caspase-mediated proteolytic cleavage.

Authors:  P Y Goh; Y J Tan; S P Lim; S G Lim; Y H Tan; W J Hong
Journal:  Virology       Date:  2001-11-25       Impact factor: 3.616

7.  Raf-1 kinase associates with Hepatitis C virus NS5A and regulates viral replication.

Authors:  T Bürckstümmer; M Kriegs; J Lupberger; E K Pauli; S Schmittel; E Hildt
Journal:  FEBS Lett       Date:  2005-12-29       Impact factor: 4.124

8.  Cytoplasmic tail phosphorylation of the alpha-factor receptor is required for its ubiquitination and internalization.

Authors:  L Hicke; B Zanolari; H Riezman
Journal:  J Cell Biol       Date:  1998-04-20       Impact factor: 10.539

9.  Insertion of green fluorescent protein into nonstructural protein 5A allows direct visualization of functional hepatitis C virus replication complexes.

Authors:  Darius Moradpour; Matthew J Evans; Rainer Gosert; Zhenghong Yuan; Hubert E Blum; Stephen P Goff; Brett D Lindenbach; Charles M Rice
Journal:  J Virol       Date:  2004-07       Impact factor: 5.103

10.  Hepatitis C virus (HCV) NS5A protein: role in HCV replication and resistance to interferon-alpha.

Authors:  J M Pawlotsky
Journal:  J Viral Hepat       Date:  1999-07       Impact factor: 3.728

View more
  168 in total

Review 1.  Hepatitis C virus: assembly and release of virus particles.

Authors:  Daniel M Jones; John McLauchlan
Journal:  J Biol Chem       Date:  2010-05-10       Impact factor: 5.157

2.  A genetic interaction between the core and NS3 proteins of hepatitis C virus is essential for production of infectious virus.

Authors:  Daniel M Jones; Ali M Atoom; Xiaozhen Zhang; Shyamasundaran Kottilil; Rodney S Russell
Journal:  J Virol       Date:  2011-09-28       Impact factor: 5.103

3.  Measuring antiviral activity of benzimidazole molecules that alter IRES RNA structure with an infectious hepatitis C virus chimera expressing Renilla luciferase.

Authors:  Shuanghu Liu; Cassie A Nelson; Li Xiao; Ling Lu; Punit P Seth; Darrell R Davis; Curt H Hagedorn
Journal:  Antiviral Res       Date:  2010-11-12       Impact factor: 5.970

4.  Novel mutations in a tissue culture-adapted hepatitis C virus strain improve infectious-virus stability and markedly enhance infection kinetics.

Authors:  Maria V Pokrovskii; Caroline O Bush; Rudolf K F Beran; Margaret F Robinson; Guofeng Cheng; Neeraj Tirunagari; Martijn Fenaux; Andrew E Greenstein; Weidong Zhong; William E Delaney; Matthew S Paulson
Journal:  J Virol       Date:  2011-02-02       Impact factor: 5.103

Review 5.  Unique ties between hepatitis C virus replication and intracellular lipids.

Authors:  Eva Herker; Melanie Ott
Journal:  Trends Endocrinol Metab       Date:  2011-04-15       Impact factor: 12.015

6.  Analysis of interferon signaling by infectious hepatitis C virus clones with substitutions of core amino acids 70 and 91.

Authors:  Yusuke Funaoka; Naoya Sakamoto; Goki Suda; Yasuhiro Itsui; Mina Nakagawa; Sei Kakinuma; Takako Watanabe; Kako Mishima; Mayumi Ueyama; Izumi Onozuka; Sayuri Nitta; Akiko Kitazume; Kei Kiyohashi; Miyako Murakawa; Seishin Azuma; Kiichiro Tsuchiya; Mamoru Watanabe
Journal:  J Virol       Date:  2011-04-13       Impact factor: 5.103

Review 7.  Lipids and RNA virus replication.

Authors:  Kouacou V Konan; Lorena Sanchez-Felipe
Journal:  Curr Opin Virol       Date:  2014-09-28       Impact factor: 7.090

Review 8.  Hepatitis C Virus-Genotype 3: Update on Current and Emergent Therapeutic Interventions.

Authors:  Steven W Johnson; Dorothea K Thompson; Brianne Raccor
Journal:  Curr Infect Dis Rep       Date:  2017-06       Impact factor: 3.725

9.  Modulation of hepatitis C virus genome encapsidation by nonstructural protein 4B.

Authors:  Qingxia Han; David Manna; Kerry Belton; Richard Cole; Kouacou V Konan
Journal:  J Virol       Date:  2013-04-24       Impact factor: 5.103

10.  DEB025 (Alisporivir) inhibits hepatitis C virus replication by preventing a cyclophilin A induced cis-trans isomerisation in domain II of NS5A.

Authors:  Lotte Coelmont; Xavier Hanoulle; Udayan Chatterji; Carola Berger; Joke Snoeck; Michael Bobardt; Precious Lim; Inge Vliegen; Jan Paeshuyse; Grégoire Vuagniaux; Anne-Mieke Vandamme; Ralf Bartenschlager; Philippe Gallay; Guy Lippens; Johan Neyts
Journal:  PLoS One       Date:  2010-10-27       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.